Kingsoft Cloud Holdings Limited vs Novavax Inc — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Novavax Inc trades at $12.7 (market cap $1.82B). The key difference: Kingsoft Cloud Holdings Limited is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Novavax Inc for 59 Days on average.
| KC | NVAX | |
|---|---|---|
Market Cap | $2.71B | $1.82B |
Volume | 1,993,765 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $18.21 | $12.56 |
52-Week Low | $8.58 | $6.22 |
Typical Hold Time | 12 Days | 59 Days |
Enterprise Value | $3.03B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.33% with bearish technical indicators but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. Despite negative net margins, gross margins improved significantly to 15.05% as AI cloud services drive growth. Cash flow from operations reached $3.8 billion in 2025, though 2026 projections show negative net cash flow.
KC presents a compelling turnaround story with AI-driven growth potential, trading at attractive valuation multiples (P/S: 1.58, EV/EBITDA: 2,203). However, persistent losses and negative cash flow projections for 2026 pose significant execution risks. The 70% analyst buy rating and 60% upside potential must be weighed against the bearish technical picture and competitive cloud market dynamics.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →